Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1349221-71-1

C22H23F3N4O4S is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1349221-71-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1349221-71-1 Structure

  • Basic information

    1. Product Name: C22H23F3N4O4S
    2. Synonyms: C22H23F3N4O4S
    3. CAS NO:1349221-71-1
    4. Molecular Formula:
    5. Molecular Weight: 496.51
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1349221-71-1.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: C22H23F3N4O4S(CAS DataBase Reference)
    10. NIST Chemistry Reference: C22H23F3N4O4S(1349221-71-1)
    11. EPA Substance Registry System: C22H23F3N4O4S(1349221-71-1)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1349221-71-1(Hazardous Substances Data)

1349221-71-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1349221-71-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,4,9,2,2 and 1 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1349221-71:
(9*1)+(8*3)+(7*4)+(6*9)+(5*2)+(4*2)+(3*1)+(2*7)+(1*1)=151
151 % 10 = 1
So 1349221-71-1 is a valid CAS Registry Number.

1349221-71-1Relevant articles and documents

Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

Chiu, Hao-Chieh,Lee, Su-Lin,Kapuriya, Naval,Wang, Dasheng,Chen, Yi-Ru,Yu, Sung-Liang,Kulp, Samuel K.,Teng, Lee-Jene,Chen, Ching-Shih

, p. 4653 - 4660 (2012/08/29)

Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1349221-71-1